Mubadala Capital and Exor Ventures led a $50m Series B round extension in Iambic Therapeutics, a clinical-stage biotechnology company, with participation from Qatar Investment Authority, and existing investors Abingworth, Illumina Ventures, Nexus Venture Partners, Coatue, and Tao Capital Partners. The extension adds to an oversubscribed $100m Series B that closed in October and was co-led by Ascenta Capital and Abingworth and joined by NVIDIA and others.